INAB
IN8bio, Inc. - Common Stock (INAB)
$14
About IN8bio, Inc. - Common Stock (INAB)
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Details
Daily high
$1.16
Daily low
$1.06
Price at open
$1.06
52 Week High
$2.73
52 Week Low
$0.88
Market cap
10.4M
Dividend yield
-
Volume
41,799
Avg. volume
34,334
P/E ratio
-.57
IN8bio, Inc. - Common Stock News
Details
Daily high
$1.16
Daily low
$1.06
Price at open
$1.06
52 Week High
$2.73
52 Week Low
$0.88
Market cap
10.4M
Dividend yield
-
Volume
41,799
Avg. volume
34,334
P/E ratio
-.57